Physician profile
Vanee V Virasch
NPI 1740459403
$3,048.17
in general payments reported to CMS, 2019-2025
17 companies · $1,609 in 2025
The $1,609 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.98 · 2020: $203 · 2021: $287 · 2022: $181 · 2023: $143 · 2024: $537 · 2025: $1,609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,500 · Food and Beverage: $788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,500.00 |
| Food and Beverage | $788.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $2,064.40 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Alcon Vision LLC | $207.80 | 2019-2023 | Clareon, Rocklatan |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $147.74 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $125.22 | 2020-2022 | |
| Aerie Pharmaceuticals, INC. | $88.66 | 2021 | |
| Harrow Eye, LLC | $81.53 | 2024-2025 | Vevye |
| Akorn Operating Company LLC | $75.12 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $62.93 | 2019-2023 | Tecnis Simplicity |
| Abbvie INC. | $30.35 | 2022 | |
| Allergan, INC. | $30.12 | 2020-2021 | |
| Thea Pharma INC. | $23.08 | 2022 | |
| Biotissue Holdings INC. | $22.66 | 2021 | |
| Sun Pharmaceutical Industries INC. | $21.53 | 2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Beaver-Visitec International, INC. | $18.05 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $16.71 | 2023 | Dextenza |
| Maculogix, INC. | $12.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanee Virasch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.